Latest News

Can Cannabis Help to Reduce Diabetes Risk?


 

FROM ADA 2024

Bring On the CannaVan

The team’s next step, currently underway, is to get an acute response to cannabis with an oral glucose tolerance test that’s done immediately after the participant uses a product. Since cannabis is a schedule-1 drug, it can’t be taken into the laboratory. Therefore, the researchers are using a CannaVan — a mobile lab. “We drive it to their homes, they come out, we draw blood, and we send them back into their homes to use as much of their product as they want,” Bryan explained. “They come back out to the van. They do all the follow-up assessments. We take blood again to verify their exposure. And that’s how we collect those data.”

“Invite me back next year, and I will tell you what we found,” she quipped.

Dr. Bryan had no disclosures to report.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Diabetic Foot Infections: A Peptide’s Potential Promise
MDedge Endocrinology
Compounded Semaglutide: How to Better Ensure Its Safety
MDedge Endocrinology
Pancreatic Gene Therapy: A ‘One-and-Done’ GLP-1 Treatment?
MDedge Endocrinology
Does Semaglutide Reduce Inflammation?
MDedge Endocrinology
Exercise Plus GLP-1 RAs Upped Weight Loss, Bone Retention
MDedge Endocrinology
Triple Therapy May Be Effective in Drug-Naive T2D
MDedge Endocrinology
What Should Be Prioritized in Managing Early Diabetes?
MDedge Endocrinology
Facial Temperature Can Reveal Age and Disease
MDedge Endocrinology
GLP-1 Thyroid Warning Could Increase Overdiagnosis
MDedge Endocrinology
Can Response to Semaglutide Be Predicted With a Genetic Test?
MDedge Endocrinology